Total medical devices industry venture financing deals worth $177.4m were announced in Asia-Pacific in October 2022, led by $100m venture financing of Xunshi Technology, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 12.2% over the previous month of $201.88m and a drop of 59.1% when compared with the last 12-month average of $433.52m.
Asia-Pacific held a 19.07% share of the global medical devices industry venture financing deal value that totalled $929.98m in October 2022. With a 17.27% share and deals worth $160.65m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, Asia-Pacific recorded 21 deals during October 2022, marking a decrease of 43.24% over the previous month and a drop of 43.24% over the 12-month average. China recorded 16 deals during the month.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAsia-Pacific medical devices industry venture financing deals in October 2022: Top deals
The top five medical devices industry venture financing deals accounted for 88.2% of the overall value during October 2022.
The combined value of the top five medical devices venture financing deals stood at $156.49m, against the overall value of $177.4m recorded for the month.
The top five medical devices industry venture financing deals of October 2022 tracked by GlobalData were:
1) Chende Capital, SoftBank Vision Fund 2, Yiheng Capital Partners, Yuanyi Capital and Zhongwei Capital HoldingLimited’s $100m venture financing deal with Xunshi Technology
2) The $15m venture financing of Shenzhen Jinbaihui Biological by Bank of China Guangdong Finance
3) Longping Biosciences, Qianhai Great Wall Fund Management (Shenzhen) and Qiluo Investment’s $13.89m venture financing deal with Shenzhen Sailu Medical Technology
4) The $13.8m venture financing of Hangzhou Shenluo Medical Technology by Boyuan Capital and SDIC Chuanghe Fund Management
5) Changan Huitong, October Capital, Season Ventures and Yinglian Health Fund’s $13.8m venture financing deal with Zhejiang Pushkang Biotechnology
